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Abstract After 4 years of early benefit assessment
(EBA) in Germany, it is becoming evident that the Federal
Joint Committee (FJC) frequently considers well-estab-
lished clinical endpoints as not being relevant to patients.
Focusing on assessments of oncology medicines, we
analysed the FJC’s view on primary endpoints and com-
pared it with the approach used by regulatory authorities.
Mortality data were accepted by both stakeholders.
Whereas regulatory authorities accepted primary morbidity
endpoints such as progression-free survival and response
rates, the FJC mostly excluded these from its assessments.
Health-related quality of life (HRQoL) data have been
poorly reflected in the approval process; for EBAs, those
data have rarely impacted on benefit ratings. We argue that
agreement between regulatory authorities and the FJC is
required regarding primary study endpoints that are rele-
vant to patients, and that clarification of acceptable end-
points by the FJC, especially in the morbidity domain, has
to be provided. Moreover, in order to fully acknowledge
the benefit of a new medicinal product, mortality, mor-
bidity and HRQoL should be weighted differentially,
according to the condition.
Key Points
Alignment between regulatory bodies and the
Federal Joint Committee regarding the relevance of
primary endpoints to patients in oncology clinical
trials is required early on in clinical development in
order to facilitate the generation of appropriate data.
Evaluation of additional benefit should be performed
taking into account the condition and the disease
stage. Endpoints in the three dimensions of
mortality, morbidity and health-related quality of life
should be selected and their relevance weighted
carefully.
1 Introduction
Since the introduction of the Act on the Reform of the
Market for Medicinal Products (AMNOG) in Germany in
2011, the Federal Joint Committee (FJC) is charged with
the early benefit assessment (EBA) of medicines entering
the German market [1]. The health technology assessment
(HTA) process itself and the subsequent pricing of phar-
maceuticals in Germany are important for reimbursement
decisions in many European countries.
The aims of drug evaluation by the FJC and regulatory
authorities clearly differ. While regulatory bodies focus on
a balanced benefit–risk profile of a new medicine, the FJC
assesses the additional benefit compared with the best
available comparative treatment. In order to determine the
additional benefit of a new medicine, the FJC re-examines
all clinical data. Although the focus of the assessments by
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regulatory bodies (benefit/risk) and the FJC (additional
benefit of a new medicine vs. best available treatment)
differs, the underlying methods and standards of evidence-
based medicine apply to both procedures.
However, early experience based on systematic reviews
of primary endpoints [2] and all endpoints used in oncol-
ogy drug assessments [3] indicate that certain endpoints
and analyses commonly used to support regulatory
approval are not necessarily considered as relevant to
patients in the EBA decision process. Based on the results
of these systematic analyses, we aim to reflect the FJC’s
practice of addressing ‘patient-relevant benefit’ and com-
pare it with the clinical assessments of the European
Medicines Agency (EMA) and US Food and Drug Ad-
ministration (FDA).
2 Regulatory View on Clinically Relevant
Endpoints in Oncology
Regulatory bodies have issued guidance on clinically
meaningful endpoints in oncology clinical trials. The FDA
suggests that overall survival (OS) remains the gold stan-
dard for demonstration of clinical benefit [4]. Alternative
endpoints in randomized controlled trials include time to
progression (TTP) and progression-free survival (PFS),
while in single-arm trials, response rates (overall response
rate or complete response) may also be used (Fig. 1).
Improvement in disease-related symptoms, as a more
recently developed endpoint, is considered a clinical ben-
efit and might be suitable for regulatory approval [4, 5].
The EMA largely supports the view of the FDA.
Acceptable primary endpoints include cure rate, OS, PFS
or disease-free survival (DFS) (Fig. 1) [6]. More recently,
the EMA has issued a reflection paper on patient-reported
outcomes (PROs) suggesting that PROs are an umbrella
term encompassing also health-related quality of life
(HRQoL). Those PROs are generally considered to carry
add-on value over conventional efficacy and safety data
from a licensing perspective [7, 8].
3 The FJC Framework on Patient-Relevant
Endpoints in Oncology
The AMNOG is embedded in the German Social Code
(SGB V §35a and §103b) [14]. According to this legal
framework, the additional benefit over an appropriate
comparative therapy may be based on the following three
benefit categories: mortality, morbidity and HRQoL
(Fig. 1) [15, 16]. The FJC rules of procedure provide some
further guidance [16]:
– Mortality: longer survival (e.g. OS).
– Morbidity: improvement in the state of health (e.g.
recovery from or abatement of the disease, long-term
freedom from or reduction in symptoms), reduction of
the duration of the disease, reduction in side-effects.
– HRQoL: improvement in the quality of life.
Within available early benefit decisions, the FJC deter-
mines patient-relevant benefit according to those three
dimensions. However, the findings of the FJC indicate that
their view on patient-relevant endpoints largely deviates
from the regulatory bodies’ view on clinically relevant
Fig. 1 Comparison of acceptance of oncology endpoints in regula-
tory and benefit assessment. DFS disease-free survival, FJC Federal
Joint Committee, EORTC QLQ European Organisation for Research
and Treatment of Cancer Quality of Life Questionnaire, HRQoL
health-related quality of life, OS overall survival, PFS progression-
free survival, TTP time to progression
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endpoints [2]. Recent analyses from the German Institute
for Quality and Efficiency in Health Care (IQWiG) state
that only around half of the available outcomes for drugs in
the EBA process have been included as patient-relevant
endpoints in the institute’s assessments [17, 18].
4 EUnetHTA View on Patient-Relevant Endpoints
In response to controversial discussions regarding the use
of endpoints in approval and HTA [2, 3, 8–11], the Euro-
pean Network for Health Technology Assessment
(EUnetHTA) developed guidelines on relevant clinical
endpoints for relative effectiveness assessment (REA).
There is consensus that patient-relevant endpoints used in
HTA should be a valid measure of clinical benefit due to
treatment. The endpoints, which can be broadly catego-
rized into mortality, morbidity and HRQoL, should
describe how a patient feels, functions and survives. Along
with mortality and morbidity, HRQoL is, therefore, one of
the major REA endpoints [12, 13]. The EUnetHTA further
emphasizes that the relevance of endpoints for REA
depends on the disease, population, treatment and decision
context [12]. Preference is clearly given to long-term or
final endpoints, whenever possible [12, 13]. Notably, even
if a trial is usually only powered for a primary endpoint, the
additional benefit of a new medicine will be assessed in
comparison to an adequate comparator on all endpoints
relevant to the disease or its treatment [12, 13]. This lack of
consideration of the hierarchy of endpoints is a hallmark of
the FJC’s appraisals.
5 Benefit Category 1: Mortality—OS as Gold
Standard
Regulatory authorities view OS as the gold standard for
demonstrating clinical benefit of oncology medicines [4–
6]. However, it can be confounded by subsequent therapies.
Furthermore, survival analysis requires long-term follow-
up and large sample sizes. In some oncological conditions,
a long period of assessment would be required to reason-
ably analyze OS.
In a recent comparison of clinical trial endpoints for
oncology medicines accepted by the EMA and considered
as patient-relevant in the FJC benefit assessment, a high
level of agreement between the two authorities with regard
to endpoints covering the benefit category of mortality was
found. OS was recognized as the preferred endpoint to
form the basis for EBA decisions in oncology [2]. One
reason for the dominance of mortality in supporting addi-
tional benefit may be the fact that unquestionable OS is
regarded as the ultimate ‘true’ endpoint [19].
Two ways of indicating a therapeutic effect on survival
for a therapy option are used: the absolute (median survival
time) and the relative value [hazard ratio (HR)] [20].
Median survival time is the time point at which the per-
centage of ‘survivors’ reaches 50 %, which might require a
long follow-up. The HR is calculated from the hazard rates,
which quantify the likelihood that a patient will experience
a ‘hazardous event’, such as disease progression or death,
during a defined time interval, within each treatment arm
[20]. Less time is needed to determine the HR, which
makes it possible to provide new promising treatments to
the patients as quickly as possible and which is of great
importance in the case of life-threatening diseases with
high medical need (e.g. metastatic melanoma). However,
median OS differences in months between the treatment
arms are primarily considered meaningful by the FJC; HRs
are less well-accepted in the EBA decisions. Although
information on absolute extension of survival is valuable, it
may be very difficult to obtain under certain circumstances
considering the chronic nature of certain oncological con-
ditions or, for example, in indolent diseases with inherently
long survival times. In this context, it is also important to
consider that reaching a pre-defined efficacy boundary,
typically based on HR, before the planned end of the study
might result in a recommendation for crossover. This will
lead to biased OS data after crossover and makes it
impossible to determine absolute differences in treatment
effects.
6 Benefit Category 2: Morbidity—The Field
of Controversy
In the absence of OS data, primary endpoints such as cure
rate, TTP, PFS and DFS are considered appropriate and
clinically meaningful by regulatory authorities [5, 6].
These endpoints are by definition not confounded by sub-
sequent treatments, and they usually require a smaller
sample size and may be more rapidly assessed [4].
An analysis of patient-relevant endpoints in oncology
proved the suitability of PFS of patients (i.e. survival of
patients without disease worsening) as a morbidity-related,
independent endpoint. In the context of disease complica-
tions, a significant improvement of PFS with acceptable
side effects was seen as a valid, clinically and patient-
relevant morbidity benefit, especially in maintenance
treatment and palliative situations [3].
There is a lack of alignment between the EMA and the
FJC with respect to morbidity endpoints. Well-established
and clinically relevant morbidity endpoints used as the
basis for regulatory approval are considered ‘not relevant
to patients’ and are, therefore, mostly excluded by the FJC
from their appraisals (Fig. 1) [2].
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The IQWiG report ‘Validity of surrogate endpoints in
oncology’ does consider OS as the ultimate ‘true’ end-
point, and all parameters of tumour response, including
response rate and progression-related outcomes, are seen
as surrogates for OS. Thus, morbidity is not a self-s-
tanding dimension and morbidity outcomes are only
acceptable when validated against mortality [19]. The
only true endpoint in morbidity that is frequently assessed
is pain [21]. However, in particular, asymptomatic
increase in tumour progression related to morbidity that is
not yet symptomatic guides clinical behaviour mainly in
early stages of the disease, but it is not considered patient
relevant.
According to the FJC, the patient relevance of PFS is not
proven. Imaging techniques to determine disease progres-
sion in accordance with the Response Evaluation Criteria
In Solid Tumors (RECIST) were regarded by the FJC as
not being relevant to patients. For example, in the assess-
ment of axitinib for renal cell carcinoma, imaging methods
were used to identify metastases in the spine, which was
not considered as relevant to patients by the FJC. In the
assessment of pertuzumab, the manufacturer suggested that
at least a change of therapeutic regimen after disease
progression should be considered relevant to patients; an
argument that was not reflected in the FJC’s final appraisal
[21]. Generally speaking, almost all asymptomatic primary
endpoints are not considered to be patient relevant by the
FJC, which does, to a certain extent, challenge the ethical
basis of the conduct of those clinical trials.
The FJC splits PFS into a mortality and symptom
component. However, as mortality is covered within OS
and symptoms are often assessed by HRQoL instruments,
the question remains what the FJC considers as a ‘true’
endpoint covering the morbidity dimension in oncology.
For example, in the recent assessment of obinutuzumab, six
morbidity-related endpoints are listed within the regulatory
summary of product characteristics (SmPC) [22], none of
which are accepted as being relevant to patients by the FJC
[21].
Clearly, this controversy needs to be resolved and the
rationale for different views on this dimension should
undergo scientific (and public) discussion. The accept-
ability of PFS might also depend on the disease stage
(e.g. adjuvant setting: PFS acceptable; metastatic setting:
PFS alone insufficient) [18, 22]. Moreover, it has to be
recognized that there are clinical circumstances under
which conclusions about OS based on PFS results are
questionable. For example, PFS may lead to longer OS
simply because patients are able to tolerate treatment for a
longer period of time and not because of superior
efficacy.
7 Benefit Category 3: HRQoL—A Field to be
Explored Further
So far, measures of HRQoL have not been used as primary
efficacy endpoints for the regulatory approval of oncology
drugs (Fig. 1) [4]. In addition, changes in signs or symp-
toms must clearly distinguish between disease symptoms
and drug toxicity.
The recent EMA reflection paper suggests that PROs are
an umbrella term covering single-dimensional and multi-
dimensional measures of symptoms, HRQoL, health status,
adherence to treatment and satisfaction with treatment.
PROs include any outcome evaluated directly by the
patients themselves and based on patients’ perception of a
disease and its treatment(s). HRQoL is a multi-domain
concept that represents patients’ general perceptions of the
effect of illness and treatment on physical, psychological
and social aspects of life. HRQoL instruments attempt to
measure complex aspects of life that may potentially be
modified by therapeutic interventions [7]. Whereas objec-
tive clinical measurements may not necessarily correlate to
patients’ own feelings of well-being, such measurements
may capture the personal and social context of the disease
and treatment experience. According to the EMA, PROs
carry add-on value over conventional efficacy and safety
data from a licensing perspective [7]. Moreover, PROs are
of increasing importance in the interpretation of survival
gains, for example, in end-stage disease. In those situa-
tions, a key treatment goal is the relief of symptoms [8].
There is no standard approach regarding collection,
analysis or interpretation of PRO data in clinical trials [23].
Careful thought must go into designing and implementing
PRO measures in oncology trials in order to investigate a
well-formulated, pre-defined hypothesis [7]. When assess-
ing HRQoL, generic instruments should be considered and
complemented with disease-specific measures if available
[13].
A high level of acceptance of HRQoL instruments by
the FJC, but poor contribution of HRQoL results to the
final EBA decision, was found due to limited acceptance of
the conducted analyses (Fig. 1) [2]. Methodological chal-
lenges, such as study-specific adaptions of questionnaires
or an inadequate return rate, have prevented notable con-
sideration in benefit assessments to date [24].
The results of HRQoL instruments were repeatedly
disregarded by the FJC; whereas single items (e.g. evalu-
ation of a specific symptom) were accepted in the mor-
bidity benefit category [2].
Measures of patients’ preferences, usually referred to as
utility measures, are currently only poorly reflected in the
FJC’s benefit decisions.
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Further study is required to address methodological
issues related to HRQoL, for example:
1. A sound conceptual framework is needed to address
the expected impact of a disease on patient symptoms
[25]. This framework should also provide clarification
regarding the different (albeit interrelated) concepts of
PROs, HRQoL and utility measurement.
2. The relevance, reliability and responsiveness of the
specific instrument/assessment, e.g. in orphan indica-
tions, should be determined.
3. Adequacy of study design, including ex ante HRQoL
hypotheses and methods for appropriate handling of
data collection (e.g. frequency and duration) as well as
statistical methods regarding missing data, should be
determined.
4. The rationale for the anticipated magnitude of effect
should be addressed: statistical significance should
correlate with clinical meaningfulness; confounding
explanations should be addressed.
8 Further Aspect: Weighting of Benefit Categories
According to Disease Indication
In an ‘ideal’ EBA scenario, additional benefit would be
based on positive findings in all three dimensions: mor-
tality, morbidity and HRQoL. However, the relative
importance of benefit categories varies between tumour
entities and disease stages. For example, in an aggressive
cancer with a high rate of mortality, for example, mela-
noma (median OS of less than 1 year [26]), an increase in
survival time is of the utmost relevance to the patient. In
contrast, in a chronic but less life-threatening disease,
such as advanced basal cell carcinoma, or in early, for
example, neo-adjuvant, therapy settings, disease morbidity
(e.g. delay in progression, pathological complete
response) becomes more important. For chronic indica-
tions where no curative treatment is available, an
improvement in morbidity or HRQoL can be of high
importance to patients and be even more meaningful than
OS [27].
Evaluation of additional benefit should, hence, be per-
formed on a disease-specific basis because of the complex
and heterogeneous nature of various conditions, and the
three dimensions of mortality, morbidity and HRQoL
should be weighted appropriately. To date, there has been
no weighting of patient relevance of the various available
endpoints by the FJC according to the respective course
and stage of diseases.
9 Recommendations
The following recommendations should be considered in
future EBAs to ensure adequate representation of patient-
relevant endpoints across all three dimensions:
1. Agreement between regulatory bodies and the FJC on
clinically meaningful endpoints that are relevant to
patients and related benefit categories is needed early
on in clinical development. This particularly applies to
primary study endpoints.
2. The FJC should provide a comprehensive list of ‘true’
oncology endpoints covering the dimension ofmorbidity.
3. Clinical trial programmes should attempt to capture
and consequently monitor endpoints related to as many
benefit categories as possible.
4. Weighting of benefit categories should reflect disease-
specific conditions and stage of disease (especially in
complex indications like oncology).
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